Company: BLCO
Filing Date: 2025-05-21
Form Type: DEFA14A
Source: 0000950103-25-006267
Chunk: 1

Company: Bausch & Lomb Corp
Filing Date: 2025-05-21
Form: DEFA14A
Chunk 1
---
 Annual Report are available at our website at www.bausch.com (under the tab “Investors” and under the subtab “SEC Filings”) or on SEDAR+ at www.sedarplus.ca or through the SEC’s electronic data system, EDGAR, at www.sec.gov. From and after the date of this Amendment, all references to the “Proxy Statement” are to the Proxy Statement as amended hereby. The Proxy Statement contains important information, and this Amendment should be read in conjunction with the Proxy Statement.

If you have already voted and would like to change or revoke your vote on any proposal, please refer to the disclosure in the Proxy Statement under “Questions About Voting—How do I vote?,” “—How do I appoint a proxyholder?” and “—If I change my mind, can I revoke my proxy once I have given it?” for more information. In connection with this Amendment, the Company is waiving the proxy deadline.

The primary purpose of this Amendment is to update the section of the Proxy Statement with the following information, which was separately disclosed on a Form 8-K filed by the Company on the date hereof:

On May 19, 2025, Bausch Health Companies Inc. (“BHC”), the majority shareholder of the Company, entered into respective letter agreements (the “Letter Agreements” and each a “Letter Agreement”) with each of (i) Carl Icahn and the other members of the Icahn Group (as such term is defined in the B+L DANA (as defined below)), (ii) John Paulson and his affiliates (the “Paulson Group”) and (iii) Sarah Kavanagh and her affiliates (the “Kavanagh Group”, and each of the Icahn Group, the Paulson Group and the Kavanagh Group, a “Group”), as overlapping directors on the Board of Directors of the Company (the “B+L Board”) and the Board of Directors of BHC (the “BHC Board”), pursuant to which, each of the Groups, respectively, have agreed that, if such Group engages in a “Specified Action” then such Group shall immediately tender their resignations from the BHC Board and the B+L Board, and (ii) in respect of the Icahn Group Letter Agreement, the Icahn Group shall irrevocably waive its rights under specified provisions of the Amended and Restated Director Appointment and Nomination Agreement dated June 21, 2022 between